About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2014 (2014), Article ID 145764, 7 pages
http://dx.doi.org/10.1155/2014/145764
Research Article

Epidemiology, Treatment Patterns, and Outcomes of Metastatic Soft Tissue Sarcoma in a Community-Based Oncology Network

1Department of Information Technology, Health Economics and Outcomes Research, McKesson Specialty Health, The Woodlands, TX, USA
2GlaxoSmithKline, Philadelphia, PA 19112, USA
3Texas Oncology, Dallas, TX, USA
4Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA
5Baylor University Medical Center at Dallas, Dallas, TX, USA
6Texas Oncology, Baylor Sammons Cancer Center, 3410 Worth Street, Dallas, TX 75246, USA

Received 22 August 2013; Revised 13 December 2013; Accepted 15 December 2013; Published 12 January 2014

Academic Editor: Charles Catton

Copyright © 2014 Clara Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. To assess epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma (mSTS) patients in USA community oncology practices. Methods. This retrospective, descriptive study used US Oncology’s iKnowMed electronic health records database. Adults (≥18 years) with mSTS and at least two visits between July 2007 and June 2010 were included. Key outcomes were practice patterns, overall survival (OS), and progression-free survival (PFS). Results. 363 mSTS patients (174 treated and 189 untreated) met the prespecified exclusion/inclusion criteria. The most common subtypes were leiomyosarcoma ( ; 29%), liposarcoma ( ; 11%), and synovial sarcoma ( ; 3%); the remainder ( ; 57%) comprised 27 histologic subtypes. Treated patients were younger and had lower ECOG scores; 75% and 25% received first-line combination or monotherapy, respectively. Median OS of treated and untreated patients was 22 and 17 months, respectively, and 29 months in patients with the three most common subtypes. Before controlling for effects of covariates, younger age and lower ECOG scores were associated with better OS and PFS. Conclusion. This study provides insights into mSTS epidemiology, treatment patterns, and outcomes in a large community-based oncology network. These results warrant further studies with larger cohorts.